Antiepileptic Drugs Market, By Generation (First Generation, Second Generation, Third Generation), By Route of Administration (Oral, Intravenous, Others (nasal, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Antiepileptic Drugs Market, By Generation (First Generation, Second Generation, Third Generation), By Route of Administration (Oral, Intravenous, Others (nasal, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Anti-epileptic drugs are prescribed for patients who suffer from seizures. The major symptom of epilepsy is repeated seizures, which are sudden bursts of electrical activity in the brain that temporarily affects the functioning of the brain. Some seizures causes the body to jerk and shake, while others cause problems such as loss of awareness or unusual sensations. Anti-epileptic drugs include a diverse class of medications that are increasingly used for conditions apart from epilepsy such as migraine prophylaxis, neuropathic pain, and bipolar disorder. Anti-epileptics are categorized in three generations as first generation, second generation and third generation. Each generation denotes a different specification. The first generation drugs includes Bromide, Phenobarbital, Primidone, and Carbamazepine, second generation drugs include Felbamate, Lamotrigine, Levetiracetam, and others, and third generation drugs includes Lacosamide, Eslicarbazepine Acetate, Clobazam and others. The third generation drugs are anticipated to register the highest CAGR over the foreascted period attributed to rise in the rise in penetration and increasing adoption of these drugs.
Market Dynamics
In order to bring new and innovative drugs to the market, key players are engaged in adopting organic organic strategies such as regulatory approval which is expected to drive the global anti-epileptic drugs market growth over the forecast period. For instance, in March 2022, UCB S.A, a biopharmaceutical company, announced that FINTEPLA (fenfluramine), a oral solution CIV had been approved in theU.S., by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients of age two years and older. LGS is a severe childhood-onset developmental and epileptic encephalopathy characterized by drug-resistant seizures.
Key features of the study:
- This report provides an in-depth analysis of the global anti-epileptic drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anti-epileptic drugs market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Shanghai Zhimeng Biopharma, Inc., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., IAMA Therapeutics, Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Marinus Pharmaceuticals, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global anti-epileptic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs market
- By Generation:
- First Generation
- Second Generation
- Third Generation
- By Route of Administration:
- Oral
- Intravenous
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- E-commerce
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- Novartis AG
- GlaxoSmithKline Plc
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Shanghai Zhimeng Biopharma, Inc.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co., Ltd.
- IAMA Therapeutics
- Angelini S.p.a
- Sun Pharmaceutical Industries Ltd.
- UCB S.A
- Marinus Pharmaceuticals, Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.
- 1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Generation
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Key Developments
- Mergers, Acquisitions and Collaborations
- Recent Trends
- Recent Launches/Approvals
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Porter’s Analysis
- 4. Global Antiepileptic Drugs Market – COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
- 5. Global Antiepileptic Drugs Market, By Generation, 2018–2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018–2030
- Segment Trends
- First Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- Second Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
- Segment Trends
- Third Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
- Segment Trends
- 6. Global Antiepileptic Drugs Market, By Route of Administration, 2018 – 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018–2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
- Segment Trends
- 7. Global Antiepileptic Drugs Market, By Distribution Channel, 2018 – 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018–2030
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
- E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
- 8. Global Antiepileptic Drugs Market, By Region, 2018 – 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018–2030
- Segment Trends
- North America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 –2030, (US$ Bn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 –2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth ,By Country, 2018 –2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 –2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 –2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, and , Y-o-Y Growth, By Country/Region, 2018 –2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
- 9. Competitive Landscape
- Company Profiles
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline Plc
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy’s Laboratories Ltd.
- Shanghai Zhimeng Biopharma, Inc.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co, Ltd
- IAMA Therapeutics
- Angelini S.p.a
- Sun Pharmaceutical Industries Ltd.
- UCB S.A
- Marinus Pharmaceuticals, Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.
- Analysts’ Views
- 10. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 37 market data tables and 31 figures on “Global Antiepileptic Drugs Market” – Global forecast to 2030
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook